US 12,187,771 B2
Method of producing Th9 T-cells
K. Christopher Garcia, Menlo Park, CA (US); Darren L. Bates, Oak Park, CA (US); and Ignacio Moraga, Palo Alto, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Aug. 7, 2020, as Appl. No. 16/988,460.
Application 15/662,180 is a division of application No. 14/419,873, granted, now 9,738,696, issued on Aug. 22, 2017, previously published as PCT/US2013/054164, filed on Aug. 8, 2013.
Application 16/988,460 is a continuation of application No. 15/662,180, filed on Jul. 27, 2017, granted, now 10,738,096.
Claims priority of provisional application 61/825,980, filed on May 21, 2013.
Claims priority of provisional application 61/725,791, filed on Nov. 13, 2012.
Claims priority of provisional application 61/681,490, filed on Aug. 9, 2012.
Prior Publication US 2021/0188932 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01); C07K 14/52 (2006.01); C07K 14/54 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/5406 (2013.01) [C07K 14/52 (2013.01); A61K 38/00 (2013.01)] 7 Claims
 
1. A method for promoting differentiation of CD4T-cells into TH9 T-cells, the method comprising providing an IL-4 mutein ligand to CD4T-cells,
wherein the IL-4 mutein is derived from the wild type human IL-4 of SEQ ID NO: 4 and comprises the amino acid substitutions K117R, T118V, R121Q, E122S, Y124W, S125F, S128G, and S129A; and
wherein the IL-4 mutein ligand binds a first shared receptor polypeptide with at least 10-fold higher affinity than the wild type human IL-4 ligand, wherein the first shared receptor polypeptide is common γ chain (γc),
thereby promoting differentiation of T-cells into TH9 T-cells.